Search

Your search keyword '"Alatab, Sudabeh"' showing total 183 results
Start Over Author "Alatab, Sudabeh"
183 results on '"Alatab, Sudabeh"'

5. Sex and age differences in inflammatory bowel disease patients; a nationwide study based on Iranian Registry of Crohn's and Colitis (IRCC).

Author

Khanmohammadi, Shaghayegh, Sheidaei, Ali, Alatab, Sudabeh, Tabatabaei-Malazy, Ozra, Vahedi, Homayoon, Mansour-Ghanaei, Fariborz, Fakheri, Hafez, Sheikhesmaeili, Farshad, Sadeghi, Anahita, Sima, Ali Reza, Anushiravan, Amir, Yazdanbod, Abbas, Moosavy, Seyed Hamid, Maleki, Iradj, Vosooghinia, Hassan, Malekzadeh, Masoud, and Malekzadeh, Reza

Subjects
INFLAMMATORY bowel diseases, AGE differences, CROHN'S disease, COLITIS, ULCERATIVE colitis
Abstract

Background: Despite the rising prevalence of Inflammatory Bowel Disease (IBD), age and sex differences in its outcomes remain understudied. We investigated age and sex differences in IBD patients using a nationwide study in Iran, the Iranian Registry of Crohn's and Colitis (IRCC). Methods: The IRCC is a national registry that gathered information on adult IBD patients since 2017. The collected data included demographic information, medication history, disease activity, comorbidities, diagnosis age, prognosis, the extent of ulcerative colitis (UC), Crohn's disease (CD) location, and extraintestinal manifestations. The statistical methods included the independent Student's t-test, Chi-square test, and binary logistic regression, using R version 4.2.2. Results: Among the 9,392 IBD patients, 7,496 (3,600 females) and 1,896 (808 females) had UC and CD, respectively. Sex difference showed higher odds of active disease in the past six months in male CD patients (OR 1.24 [95%CI 1.03, 1.49]) vs. females, but in male UC patients, the OR was 0.85 [0.78, 0.93]. Severe disease was less likely in CD patients aged 19–59 and >60 vs. <18. Similarly, UC patients <18 had lower odds of severe disease vs. those aged 19–59 and >60. Conclusions: This study emphasizes the importance of understanding age and sex differences in IBD outcomes. These findings contribute to the ongoing global discussion on IBD management and facilitate the development of targeted interventions and personalized care. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Clinical Phenotype and Disease Course of Inflammatory Bowel Disease: A Comparison Between Sporadic and Familial Cases

Author

Saberzadeh-Ardestani, Bahar, Anushiravani, Amir, Mansour-Ghanaei, Fariborz, Fakheri, Hafez, Vahedi, Homayoon, Sheikhesmaeili, Farshad, Yazdanbod, Abbas, Moosavy, Seyed Hamid, Vosoghinia, Hasan, Maleki, Iradj, Nasseri-Moghaddam, Siavosh, Khosravi, Bardia, Malekzadeh, Masoud, Kasaeian, Amir, Alatab, Sudabeh, Sadeghi, Anahita, Kolahdoozan, Shadi, Rayatpisheh, Maryam, Sima, Ali Reza, and Malekzadeh, Reza

Published
2022
Full Text
View/download PDF

7. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

Author

Alatab, Sudabeh, Sepanlou, Sadaf G, Ikuta, Kevin, Vahedi, Homayoon, Bisignano, Catherine, Safiri, Saeid, Sadeghi, Anahita, Nixon, Molly R, Abdoli, Amir, Abolhassani, Hassan, Alipour, Vahid, Almadi, Majid A H, Almasi-Hashiani, Amir, Anushiravani, Amir, Arabloo, Jalal, Atique, Suleman, Awasthi, Ashish, Badawi, Alaa, Baig, Atif A A, Bhala, Neeraj, Bijani, Ali, Biondi, Antonio, Borzì, Antonio M, Burke, Kristin E, Carvalho, Félix, Daryani, Ahmad, Dubey, Manisha, Eftekhari, Aziz, Fernandes, Eduarda, Fernandes, João C, Fischer, Florian, Haj-Mirzaian, Arvin, Haj-Mirzaian, Arya, Hasanzadeh, Amir, Hashemian, Maryam, Hay, Simon I, Hoang, Chi L, Househ, Mowafa, Ilesanmi, Olayinka S, Jafari Balalami, Nader, James, Spencer L, Kengne, Andre P, Malekzadeh, Masoud M, Merat, Shahin, Meretoja, Tuomo J, Mestrovic, Tomislav, Mirrakhimov, Erkin M, Mirzaei, Hamid, Mohammad, Karzan A, Mokdad, Ali H, Monasta, Lorenzo, Negoi, Ionut, Nguyen, Trang H, Nguyen, Cuong T, Pourshams, Akram, Poustchi, Hossein, Rabiee, Mohammad, Rabiee, Navid, Ramezanzadeh, Kiana, Rawaf, David L, Rawaf, Salman, Rezaei, Nima, Robinson, Stephen R, Ronfani, Luca, Saxena, Sonia, Sepehrimanesh, Masood, Shaikh, Masood A, Sharafi, Zeinab, Sharif, Mehdi, Siabani, Soraya, Sima, Ali Reza, Singh, Jasvinder A, Soheili, Amin, Sotoudehmanesh, Rasoul, Suleria, Hafiz Ansar Rasul, Tesfay, Berhe E, Tran, Bach, Tsoi, Derrick, Vacante, Marco, Wondmieneh, Adam B, Zarghi, Afshin, Zhang, Zhi-Jiang, Dirac, Mae, Malekzadeh, Reza, and Naghavi, Mohsen

Published
2020
Full Text
View/download PDF

9. Comparison of Disease Phenotype and Course among Elderly- and Early-Onset Inflammatory Bowel Diseases in the Middle East

Author

Vosoghinia, Hasan, primary, Saberzadeh-Ardestani, Bahar, additional, Anushiravani, Amir, additional, Mansour-Ghanaei, Fariborz, additional, Fakheri, Hafez, additional, Vahedi, Homayoon, additional, Sheikhesmaeili, Farshad, additional, Yazdanbod, Abbas, additional, Moosavy, Seyed Hamid, additional, Maleki, Iradj, additional, Nasseri-Moghaddam, Siavosh, additional, Khosravi, Bardia, additional, Malekzadeh, Masoud, additional, Kasaeian, Amir, additional, Alatab, Sudabeh, additional, Sadeghi, Anahita, additional, Kolahdoozan, Shadi, additional, Amani, Mohammad, additional, Saberhosseini, Seyedeh Naeimeh, additional, Rayatpisheh, Maryam, additional, Ahadi, Mitra, additional, Colombel, Jean-Frederic, additional, Ungaro, Ryan C., additional, Sima, Ali Reza, additional, and Malekzadeh, Reza, additional

Published
2023
Full Text
View/download PDF

13. Antioxidative hypoglycemic herbal medicines with in vivo and in vitro activity against C-reactive protein; a systematic review

Author

Mirahmad, Maryam, primary, Mohseni, Shahrzad, additional, Tabatabaei-Malazy, Ozra, additional, Esmaeili, Fataneh, additional, Alatab, Sudabeh, additional, Bahramsoltani, Roodabeh, additional, Ejtahed, Hanieh-Sadat, additional, Qulami, Husseyn, additional, Bitarafan, Zahra, additional, Arjmand, Babak, additional, and Nazeri, Elahe, additional

Published
2023
Full Text
View/download PDF

15. Susceptibility of Patients with Inflammatory Bowel Disease to COVID-19 Compared with Their Households

Author

Anushiravani, Amir, primary, Saberzadeh-Ardestani, Bahar, additional, Vahedi, Homayoon, additional, Fakheri, Hafez, additional, Mansour-Ghanaei, Fariborz, additional, Maleki, Iraj, additional, Nasseri-Moghaddam, Siavosh, additional, Vosoghinia, Hasan, additional, Ghadir, Mohammad Reza, additional, Hormati, Ahmad, additional, Kasaeian, Amir, additional, Radmard, Amir Reza, additional, Khosravi, Bardia, additional, Malekzadeh, Masoud, additional, Alatab, Sudabeh, additional, Sadeghi, Anahita, additional, Aminisani, Nayyereh, additional, Poustchi, Hossein, additional, Sima, Ali Reza, additional, and Malekzadeh, Reza, additional

Published
2022
Full Text
View/download PDF

18. Outcomes of COVID-19 in Patients with Inflammatory Bowel Disease: Comparison with Household Members and the Role of IBD Medications

Author

Sima, Ali Reza, primary, Saberzadeh-Ardestani, Bahar, additional, Vahedi, Homayoon, additional, Fakheri, Hafez, additional, Mansour-Ghanaei, Fariborz, additional, Maleki, Iradj, additional, Nasseri-Moghaddam, Siavosh, additional, Vosoghinia, Hasan, additional, Ghadir, Mohammad Reza, additional, Hormati, Ahmad, additional, Kasaeian, Amir, additional, Radmard, Amir Reza, additional, Khosravi, Bardia, additional, Malekzadeh, Masoud, additional, Alatab, Sudabeh, additional, Sadeghi, Anahita, additional, Aminisani, Nayyereh, additional, Poustchi, Hossein, additional, Gonoudi, Elnaz, additional, Anushiravani, Amir, additional, Rayatpisheh, Maryam, additional, Colombel, Jean-Frederic, additional, Ungaro, Ryan C., additional, and Malekzadeh, Reza, additional

Published
2022
Full Text
View/download PDF

19. A Supporting System for Management of Patients with Inflammatory Bowel Disease during COVID-19 Outbreak: Iranian Experience-Study Protocol

Author

Anushiravani, Amir, Vahedi, Homayoon, Fakheri, Hafez, Mansour-ghanaei, Fariborz, Maleki, Iradj, Nasseri-Moghaddam, Siavosh, Vosoghinia, Hasan, Ghadir, Mohammad Reza, Hormati, Ahmad, Aminisani, Nayyereh, Radmard, Amir Reza, Khosravi, Bardia, Saberzadeh-Ardestani, Bahar, Malekzadeh, Masoud, Alatab, Sudabeh, Sadeghi, Anahita, Salahi, Sarvenaz, Malekzadeh, Reza, and Sima, Ali Reza

Subjects
COVID-19, Original Article, Care, digestive system diseases, Protocols, Inflammatory bowel disease
Abstract

BACKGROUND The COVID-19 pandemic has affected the health care infrastructure dramatically, with abundant resources necessarily being redirected to COVID-19 patients and their care. Also, patients with chronic diseases like inflammatory bowel disease (IBD) may be affected in several ways during this pandemic. METHODS We used the Iranian registry of Crohn's and colitis (IRCC) infrastructure. We called and sent messages to follow-up and support the care of all registered patients. Besides, we prepared and distributed educational materials for these patients and physicians to reduce the risk of COVID-19 infection. We risk-stratified them and prepared outpatient clinics and hospitalization guidance for IBD patients. RESULTS Of 13165 Iranian patients with IBD, 51 have been diagnosed as having COVID-19. IBD patients made 1920 hotline calls. Among the patients with suspicious presentations, 14 COVID-19 infections were diagnosed. Additionally, 1782 patients with IBD from five provinces actively phone-called among whom 28 definite cases were diagnosed. CONCLUSION IBD patients' follow-up could help in diagnosing the affected IBD patients with COVID-19. Additionally, the performance of protective actions and preparing the patients and physicians for decisive proceedings are the principles of protection of IBD patients.

Published
2020

21. Clinical Phenotype and Disease Course of Inflammatory Bowel Disease: A Comparison Between Sporadic and Familial Cases

Author

Saberzadeh-Ardestani, Bahar, primary, Anushiravani, Amir, additional, Mansour-Ghanaei, Fariborz, additional, Fakheri, Hafez, additional, Vahedi, Homayoon, additional, Sheikhesmaeili, Farshad, additional, Yazdanbod, Abbas, additional, Moosavy, Seyed Hamid, additional, Vosoghinia, Hasan, additional, Maleki, Iradj, additional, Nasseri-Moghaddam, Siavosh, additional, Khosravi, Bardia, additional, Malekzadeh, Masoud, additional, Kasaeian, Amir, additional, Alatab, Sudabeh, additional, Sadeghi, Anahita, additional, Kolahdoozan, Shadi, additional, Rayatpisheh, Maryam, additional, Sima, Ali Reza, additional, and Malekzadeh, Reza, additional

Published
2021
Full Text
View/download PDF

23. Prevalence of impaired renal function and determinants in the southwest of Iran

Author

Alvand, Saba, primary, Abolnezhadian, Farhad, additional, Alatab, Sudabeh, additional, Mohammadi, Zahra, additional, Hayati, Fatemeh, additional, Noori, Mohammad, additional, Danehchin, Leila, additional, Paridar, Yousef, additional, Cheraghian, Bahman, additional, Rahimi, Zahra, additional, Hariri, Sanam, additional, Masoudi, Sahar, additional, Mard, Seyed Ali, additional, Shayesteh, Ali Akbar, additional, and Poustchi, Hossein, additional

Published
2021
Full Text
View/download PDF

30. Systemic Infusion of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells in Peritoneal Dialysis Patients: Feasibility and Safety

Author

Alatab, Sudabeh, Shekarchian, Soroosh, Najafi, Iraj, Moghadasali, Reza, Ahmadbeigi, Naser, Pourmand, Mohammad Reza, Bolurieh, Tina, Jaroughi, Neda, Pourmand, Gholamreza, and Aghdami, Nasser

Subjects
Cellular and Molecular Biology, Mesenchymal Stem Cell, Stem Cell, lcsh:R, lcsh:Medicine, Original Article, Peritoneal Fibrosis, lcsh:Q, End Stage Renal Disease, lcsh:Science, Peritoneal Dialysis
Abstract

Objective Using mesenchymal stem cells (MSCs) is regarded as a new therapeutic approach for improving fibrotic diseases. the aim of this study to evaluate the feasibility and safety of systemic infusion of autologous adipose tissue-derived MSCs (AD-MSCs) in peritoneal dialysis (PD) patients with expected peritoneal fibrosis. Materials and Methods This study was a prospective, open-label, non-randomized, placebo-free, phase I clinical trial. Case group consisted of nine eligible renal failure patients with more than two years of history of being on PD. Autologous AD-MSCs were obtained through lipoaspiration and expanded under good manufacturing practice conditions. Patients received 1.2 ± 0.1×106 cell/kg of AD-MSCs via cubital vein and then were followed for six months at time points of baseline, and then 3 weeks, 6 weeks, 12 weeks, 16 weeks and 24 weeks after infusion. Clinical, biochemical and peritoneal equilibration test (PET) were performed to assess the safety and probable change in peritoneal solute transport parameters. Results No serious adverse events and no catheter-related complications were found in the participants. 14 minor reported adverse events were self-limited or subsided after supportive treatment. One patient developed an episode of peritonitis and another patient experienced exit site infection, which did not appear to be related to the procedure. A significant decrease in the rate of solute transport across peritoneal membrane was detected by PET (D/P cr=0.77 vs. 0.73, P=0.02). Conclusion This study, for the first time, showed the feasibility and safety of AD-MSCs in PD patients and the potentials for positive changes in solute transport. Further studies with larger samples, longer follow-up, and randomized blind control groups to elucidate the most effective route, frequency and dose of MSCs administration, are necessary (Registration Number: IRCT2015052415841N2).

Published
2018

35. Efficacy of Anti-TNF Therapy for the Treatment of Patients with Moderate-to-Severe Inflammatory Bowel Disease; a First Iranian Report

Author

Mohagheghi Darehranj, Samaneh, primary, Alatab, Sudabeh, additional, Vahedi, Homayoon, additional, Sadeghi, Anahita, additional, Sima, Alireza, additional, Malekzadeh, Masoud, additional, Anoshiravani, Amir, additional, Fakheri, Hafez, additional, Ebrahimi Daryani, Nasser, additional, Mousavi, Abdolhamid, additional, Mansour-Ghanaei, Fariborz, additional, Javad Zahedi, Mohammad, additional, and Malekzadeh, Reza, additional

Published
2019
Full Text
View/download PDF

38. Iranian Registry of Crohn’s and Colitis: study profile of first nation-wide inflammatory bowel disease registry in Middle East

Author

Malekzadeh, Masoud M, primary, Sima, Alireza, additional, Alatab, Sudabeh, additional, Sadeghi, Anahita, additional, Daryani, Nasser Ebrahimi, additional, Adibi, Payman, additional, Maleki, Iradj, additional, Vossoughinia, Hassan, additional, Fakheri, Hafez, additional, Yazdanbod, Abbas, additional, Taghavi, Seyed Alireza, additional, Aghazadeh, Rahim, additional, Somi, Mohammad Hassan, additional, Zendedel, Kazem, additional, Vahedi, Homayoon, additional, and Malekzadeh, Reza, additional

Published
2019
Full Text
View/download PDF

39. PD09-05 SYSTEMIC INFUSION OF AUTOLOGOUS ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS IN PERITONEAL DIALYSIS PATIENTS: FEASIBILITY AND SAFETY

Author

Alatab, Sudabeh, primary, Shekarchian, Soroosh, additional, Njafi, Iraj, additional, Moghadasali, Reza, additional, Pourmand, Mohammad Reza, additional, Ahmadbeigi, Naser, additional, Bolurieh, Tina, additional, Jaroughi, Neda, additional, Pourmand*, Gholamreza, additional, and Aghdami, Nasser, additional

Published
2019
Full Text
View/download PDF

42. Efficacy of Anti-TNF Therapy for the Treatment of Patients with Moderate-to-Severe Inflammatory Bowel Disease; a First Iranian Report.

Author

Darehranj, Samaneh Mohagheghi, Alatab, Sudabeh, Vahedi, Homayoon, Sadeghi, Anahita, Sima, Alireza, Malekzadeh, Masoud, Anoshiravani, Amir, Fakheri, Hafez, Daryani, Nasser Ebrahimi, Mousavi, Abdolhamid, Mansour-Ghanaei, Fariborz, Zahedi, Mohammad Javad, and Malekzadeh, Reza

Subjects
*RISK factors of pneumonia, *DRUG side effects, *INFLAMMATORY bowel diseases, *INTERVIEWING, *MUSCULOSKELETAL system, *PATIENT safety, *RISK assessment, *TELEPHONES, *INFLIXIMAB, *TERMINATION of treatment, *TREATMENT effectiveness, *SEVERITY of illness index, *ADULTS
Abstract

BACKGROUND The anti-TNF drugs are shown to be highly effective in treatment of patients with moderate-tosevere inflammatory bowel disease (IBD). Here, we aimed to assess the efficacy and safety of anti- TNF therapy at the national level. METHODS IBD patients aged 15 > years who received Infliximab and/or CinnoRA® between 2013 to July 2018 were identified. The data extracted from medical dossier and telephonic interview. The efficacy of therapy was defined as time to drug discontinuation or need for IBD-related surgery. The safety was assessed based on patient's reported adverse events. RESULTS We included 315 patients. The mean age of patients was 37.2 years and 62.2% of them developed the disease before age 30 years. Involvement of masculoskeletal system was reported in 7.3% of patients. Partial and complete response to Anti-TNF therapy was seen in 67% of patients. About 16% of patients did not respond to induction therapy and 16.9% of patients lost their response to Anti-TNF during one year. No serious adverse events, serious opportunistic infection, tuberculosis and malignancies reported by patients. Two patients reported pneumonia. CONCLUSION This study for the first time in our country, provides the evidences for efficacy of anti-TNF therapy in moderate to severe IBD patients. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

47. Strategies for Prevention and Treatment of Peritoneal Fibrosis: A Scientometric Study.

Author

Alatab, Sudabeh, Najafi, Iraj, Tabatabaei-Malazy, Ozra, Pourmand, Gholamreza, and Ahmadbeigi, Naser

Subjects
*FIBROSIS, *PERITONEAL dialysis, *PREVENTION, *PERITONEUM
Abstract

Background: Interest in using peritoneal dialysis (PD) shows global and national increase. However, it remains a challenge to prevent the progression of PD-associated fibrosis in clinical practice. Here, we assessed the status of scientific publications in prevention and management of PD-associated fibrosis in a scientometric study. Methods: We retrieved the bibliometric data by search terms "encapsulating peritoneal fibrosis," "treatment or prevention," and their synonyms in the Scopus databases until December 2, 2017. Data were analyzed using Scopus analysis tools, SPSS version 15 and Visualizing Scientific Landscapes viewer version 1.6.5. Results: Number of publications showed a steady significant increase (P < 0.001) reaching to 390 documents. Japan had the highest share (21.3%) followed by United Kingdom. Coauthorship network assessment assigned "Ikeda M." from Japan as the top author. The top source of documents was "Peritoneal Dialysis International." Most of documents were original articles focusing on prevention and management of malignant fibrosis of peritoneum (72.6%). The documents were cited totally 5636 times with average citations per article of 14.45, and relatively high H-index of 38. Conclusions: Despite the global increasing trend in scientific output in this field, contribution of our country is very small. Perhaps more national and international collaboration is required to encourage our researchers for producing more scientific products. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

48. Systemic Infusion of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells in Peritoneal Dialysis Patients: Feasibility and Safety.

Author

Alatab, Sudabeh, Shekarchian, Soroosh, Najafi, Iraj, Moghadasali, Reza, Ahmadbeigi, Naser, Pourmand, Mohammad Reza, Bolurieh, Tina, Jaroughi, Neda, Pourmand, Gholamreza, and Aghdami, Nasser

Subjects
*MESENCHYMAL stem cells, *FIBROSIS, *PERITONEAL dialysis, *KIDNEY failure, *ADIPOSE tissues, *PLACEBOS, *THERAPEUTIC complications
Abstract

Objective: Using mesenchymal stem cells (MSCs) is regarded as a new therapeutic approach for improving fibrotic diseases. The aim of this study to evaluate the feasibility and safety of systemic infusion of autologous adipose tissue-derived MSCs (AD-MSCs) in peritoneal dialysis (PD) patients with expected peritoneal fibrosis. Materials and Methods: This study was a prospective, open-label, non-randomized, placebo-free, phase I clinical trial. Case group consisted of nine eligible renal failure patients with more than two years of history of being on PD. Autologous AD-MSCs were obtained through lipoaspiration and expanded under good manufacturing practice conditions. Patients received 1.2 ± 0.1×106 cell/kg of AD-MSCs via cubital vein and then were followed for six months at time points of baseline, and then 3 weeks, 6 weeks, 12 weeks, 16 weeks and 24 weeks after infusion. Clinical, biochemical and peritoneal equilibration test (PET) were performed to assess the safety and probable change in peritoneal solute transport parameters. Results: No serious adverse events and no catheter-related complications were found in the participants. 14 minor reported adverse events were self-limited or subsided after supportive treatment. One patient developed an episode of peritonitis and another patient experienced exit site infection, which did not appear to be related to the procedure. A significant decrease in the rate of solute transport across peritoneal membrane was detected by PET (D/P cr=0.77 vs. 0.73, P=0.02). Conclusion: This study, for the first time, showed the feasibility and safety of AD-MSCs in PD patients and the potentials for positive changes in solute transport. Further studies with larger samples, longer follow-up, and randomized blind control groups to elucidate the most effective route, frequency and dose of MSCs administration, are necessary (Registration Number: IRCT2015052415841N2). [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

49. MP88-14 ROLE OF STEROID HORMONE RECEPTORS IN FORMATION AND PROGRESSION OF BLADDER CARCINOMA: A CASE-CONTROL STUDY

Author

Pourmand, Gholamreza, primary, Mashhadi, Rahil, additional, Kosari, Farid, additional, Mehrsai, Abdolrasoul, additional, Salem, Sepehr, additional, Pourmand, Mohammad Reza, additional, Alatab, Sudabeh, additional, Khonsari, Mehdi, additional, Heydari, Fariba, additional, Beladi, Laleh, additional, and Alizadeh, Farimah, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results